Generate Biomedicines IPO: revenue, losses and offering terms from its S-1
Generate Biomedicines priced its IPO at $16 a share on 27 Feb 2026 and raised $400 million. Its shares trade on Nasdaq as GENB. Revenue was $31.9 million in 2025, up 56% from 2024, with a net loss of $223 million.
Headlines
- Revenue, 2025
- $32M
- Up 56% on the year before
- Net loss, 2025
- $223M
- IPO price
- $16
- $400M raised
Generate Biomedicines IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- GENB
- IPO price
- $16
- Shares offered
- 25,000,000
- Raised
- $400M
- Registered
- $489M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor
- First filed
- 4 Feb 2026
Generate Biomedicines revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $20M | - | -$181M |
| 2025 | $32M | -$235M | -$223M |
Generate Biomedicines share structure and company facts
- Employees
- 312
- Headquarters
- Somerville, MA
Generate Biomedicines shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 27 Feb 2026
- First close
- $12.65
- -21% on the IPO price
- Latest close
- $12.35
- -23% on the IPO price
Generate Biomedicines's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Generate Biomedicines's newest prospectus (424B4 filed 27 Feb 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.